I am an internist and medical oncologist who specializes in the care of patients with leukemia and bone marrow failure syndromes, including acute myeloid leukemia and the myelodysplastic syndromes. As a member of the Leukemia Service at Memorial Sloan Kettering Cancer Center, I am committed to partnering with each of my patients to offer them the best possible care, incorporating innovative new therapies whenever possible.
In the laboratory I study molecular alterations in the hematopoietic (blood-forming) stem and progenitor cells that underlie the development of acute myeloid leukemia and the myelodysplastic syndromes. We believe that by studying these immature blood cells we will improve our understanding of what causes these diseases, as well as the mechanisms by which they may become resistant to standard therapies. I am also interested in identifying novel alterations in cell surface protein expression in these diseases to identify new therapeutic targets and to develop new diagnostic tests.
- Clinical Expertise: The Myelodysplastic Syndromes; Acute Myeloid Leukemia
- Languages Spoken: English
- Education: MD, Washington University at St. Louis
- Residencies: Internal Medicine - Massachusetts General Hospital
- Fellowships: Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine
Chung SS, Hu W, Park CY. THe Role f MicroRNAs in Hematopoietic Stem Cell and Leukemic Stem Cell Function. Therapeutic Advances in Hematology. 2011 Oct 1;2(5):317-334.
Dey BR, chung S, Spitzer TR, Zheng H, MacGillivray TE, Seldin DC, McAfee S, Ballen KK, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen, JC, Semigran M. Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem Cell Transplantation for AL Amyloidosis and Heart Failure. Transplantation. 2010 Oct 27; 90(8);905-11
Steet R, Chung S, Lee WS, Pine CW, Do H, Kirnfeld S. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidease. Biochem Pharmacol, 2007 May 1;73(9):1376-83.
Steet RA, Chung S, Wstman B, Powe A, Do H, Kornfeld SA. The iminosugar isofagomine increases the activite of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. PNAS 2006 Sep 12;103(37):13813-8.
Boadi T, Schneider E, Chung S, Tsai L, Gettie A, Ratinirer M, Blanchard J, Neumath A, Cheng-Mayer C. Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian-huma immunodeficiency viruses. AIDS. 2005 Oct 13;19(15):1587-94.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Stephen S. Chung
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more